Hanrhoid-B100 mg+33.33 mg+16.67 mg

Hanrhoid-B is a traditional Ayurvedic herbal combination product used as a dietary/herbal supplement. Its use is based on long-standing traditional practice and preliminary studies on its individual components rather than large-scale, robust clinical trials on the specific combination itself.

• Traditional/dietary supplement use: Hanrhoid-B is traditionally used to support healthy lipid (cholesterol) metabolism, general metabolic health, and digestive function.
• Digestive support: Traditionally used as a mild digestive tonic and to support regular bowel function.
• General wellness/adjunct use: Often used as an adjunct to diet and lifestyle measures for metabolic wellness, not as a replacement for prescribed medical therapy.

Hanrhoid-B is not an FDA-approved drug and is not intended to diagnose, treat, cure, or prevent any disease. Evidence supporting its use is limited to traditional use and small preliminary studies of individual components (guggul, berberine-containing barberry, and Terminalia chebula); it should not replace evidence-based medical treatment for diagnosed conditions such as dyslipidemia or diabetes.

Guggul + Barberry + Chebulic Myrobalan is a fixed combination of three traditional botanical ingredients:

• Guggul (oleo-gum-resin of Commiphora mukul) - traditionally used for lipid metabolism and anti-inflammatory support.
• Barberry (Berberis species, standardized to contain berberine) - traditionally used for metabolic and digestive support.
• Chebulic Myrobalan (Terminalia chebula, also known as Haritaki) - traditionally used as a digestive and mild detoxifying tonic.

Exact strengths and standardization of each component may vary by manufacturer; refer to the specific product label for quantitative composition.

Hanrhoid-B is a multi-herb Ayurvedic formulation combining three botanicals with a long history of traditional use in South Asian medicine systems. It is marketed as a dietary/herbal supplement rather than as a conventional pharmaceutical drug.

Guggul resin has traditionally been used to support healthy cholesterol and triglyceride levels and for its anti-inflammatory properties. Barberry contains berberine, an alkaloid studied for effects on blood glucose and lipid parameters. Chebulic myrobalan (haritaki) is one of the most widely used botanicals in Ayurveda, traditionally valued for digestive regulation and mild laxative/detoxifying effects.

As a combination product, Hanrhoid-B has not been evaluated in large randomized controlled trials; its traditional reputation and the preliminary evidence on its individual constituents form the basis for its current use.

Hanrhoid-B belongs to the class of traditional Ayurvedic herbal/dietary supplements used for metabolic and digestive support. It is not classified as a conventional pharmaceutical (e.g., not a statin, not an oral antidiabetic drug), and should not be substituted for prescribed medications for diagnosed medical conditions.

Mechanism of Action (Traditional and Preliminary Pharmacological Basis)

Guggul + Barberry + Chebulic Myrobalan combines three botanicals whose individual constituents have been studied for the following actions, though the combination product itself has not been comprehensively studied:

• Guggul: Guggulsterones, the active constituents of guggul, have been proposed to influence lipid metabolism (possibly via effects on nuclear bile-acid receptors) and to exert mild anti-inflammatory activity.
• Barberry (berberine): Berberine has been studied for effects on AMP-activated protein kinase (AMPK) signaling, which may influence glucose uptake and lipid metabolism, along with mild antimicrobial and digestive effects.
• Chebulic Myrobalan (Haritaki): Rich in tannins and polyphenols; traditionally attributed with mild laxative, antioxidant, and digestive-tonic properties.

These mechanisms are drawn largely from studies of the isolated components; the pharmacokinetics and pharmacodynamics of Guggul + Barberry + Chebulic Myrobalan as a fixed combination have not been formally characterized.

Hanrhoid-B is generally taken orally, with or immediately after food, with a full glass of water, to reduce the chance of digestive upset. Capsules/tablets should be swallowed whole and not crushed or chewed unless the product labeling specifically permits this.

• Thyroid medications: Guggul may affect thyroid hormone levels or thyroid function tests; concurrent use with levothyroxine or other thyroid medications should be supervised by a physician, with monitoring of thyroid function as needed.
• Antidiabetic drugs/insulin: Barberry (berberine) may lower blood glucose. Concurrent use of Hanrhoid-B with insulin or oral hypoglycemic agents may increase the risk of hypoglycemia; blood glucose monitoring is advised.
• Lipid-lowering drugs: Because guggul and berberine may independently affect lipid levels, combining Hanrhoid-B with prescription lipid-lowering therapy should be done under medical supervision to avoid additive effects or masking of treatment response.
• Anticoagulant/antiplatelet drugs: Some traditional sources note a theoretical increased bleeding risk when herbal lipid-modifying agents are combined with anticoagulants; caution and medical advice are recommended.
• CYP450-metabolized drugs: Berberine has been reported to influence certain cytochrome P450 enzymes in preliminary studies; concurrent use with narrow-therapeutic-index drugs metabolized by these pathways should be discussed with a physician.

Always inform your physician or pharmacist about all prescription drugs, over-the-counter medicines, and herbal supplements being taken before starting Hanrhoid-B.

Reported side effects of Hanrhoid-B are generally mild and related to its digestive/herbal constituents:

• Gastrointestinal upset - nausea, abdominal discomfort, loose stools, or diarrhea (particularly with chebulic myrobalan at higher doses).
• Skin rash or itching (allergic reaction to a plant component).
• Headache or mild dizziness (reported occasionally with guggul).
• Low blood sugar symptoms (from the barberry/berberine component) in susceptible individuals, especially when combined with antidiabetic medication.

Discontinue use and seek medical advice if a persistent or severe reaction occurs.

Pregnancy: Hanrhoid-B should be avoided during pregnancy. Several of its traditional botanical components have a reputation for uterine-stimulant and/or purgative effects, and safety in pregnancy has not been established. Use only if a qualified physician specifically advises it, and only if the potential benefit is judged to justify potential risk to the fetus.

Lactation: There is insufficient reliable data on the excretion of the active constituents of Hanrhoid-B into breast milk or on their effects on a nursing infant. Use during breastfeeding is not recommended unless a physician determines that the benefit clearly outweighs the potential risk; consult a physician before use.

• Use Hanrhoid-B under the guidance of a qualified healthcare practitioner, particularly for individuals with pre-existing thyroid disease, diabetes, or bleeding disorders (see Interactions).
• Patients with thyroid disorders should have thyroid function monitored if using Hanrhoid-B long-term, due to guggul's potential effect on thyroid hormone levels.
• Diabetic patients or those on blood-glucose-lowering medication should monitor blood sugar closely, as the barberry component may have a hypoglycemic effect.
• Higher doses may produce a laxative effect due to the chebulic myrobalan component; reduce the dose if loose stools occur.
• Hanrhoid-B is not a substitute for prescribed treatment of diagnosed medical conditions such as hyperlipidemia, hypothyroidism, or diabetes; do not stop or replace prescribed medication with this supplement without consulting a physician.
• Discontinue and consult a physician if signs of an allergic reaction, persistent gastrointestinal symptoms, or unexpected changes in thyroid or glucose status occur.

Specific human overdose data for Hanrhoid-B are not well documented. Excessive intake may be expected to worsen the typical side effects, particularly gastrointestinal upset (diarrhea, abdominal cramping) and, theoretically, hypoglycemia due to the berberine component. If overdose or accidental ingestion of a large amount is suspected, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Use with caution; elderly patients are more likely to be on concurrent medications (e.g., for thyroid disease, diabetes, or blood thinning) that may interact with Hanrhoid-B (see Interactions). Start at the lowest labeled dose.
• Renal impairment: No well-established dose adjustment data exist; use with caution and under medical supervision.
• Hepatic impairment: No well-established dose adjustment data exist; use with caution and under medical supervision, as herbal constituents are hepatically metabolized.
• Pediatric population: See Pediatric Uses.
• Pregnancy and lactation: See Pregnancy and Lactation section.

Hanrhoid-B is generally intended for short- to medium-term use as directed on the product label or by a healthcare practitioner. Long-term continuous use beyond a few months should be reviewed periodically with a physician, particularly to monitor thyroid function and blood glucose where relevant.

Traditional Ayurvedic herbal/dietary supplement combination (lipid-metabolism and digestive-support botanical blend).

Guggul + Barberry + Chebulic Myrobalan does not have a single defined pharmacological mode of action, as it is a multi-component herbal blend. Its constituents are traditionally understood to act via mild effects on lipid metabolism (guggul), glucose/lipid-related cellular signaling (berberine from barberry), and digestive/bowel regulation (chebulic myrobalan), based on traditional use and preliminary studies of the isolated components rather than a single, well-characterized mechanism for the combination.

The safety and efficacy of Hanrhoid-B in children have not been established. Use in pediatric populations is not recommended unless specifically advised and supervised by a qualified pediatric healthcare practitioner, given the lack of controlled safety data in this age group.